International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Since Year 2012 | Open Access | Fully Refereed | Peer Reviewed

ISSN: 2319-7064




Downloads: 1

Case Studies | Health and Medical Sciences | Indonesia | Volume 11 Issue 4, April 2022


Intravenous Immunoglobulin Treatment on a Patient Presenting with Severe COVID-19 and Impending Respiratory Failure: A Case Report

Ary Priadnyana | Anak Agung Gde Upeksha [3]


Abstract: Background: As of February 2022, COVID-19 virus pandemic still plagues the earth with cases mostly related to the emergence of new variant, Omicron. Even after 2 years since its discovery, no mainstay of therapy has been established for severe-critical COVID-19. Amongst the proposed options of therapy, IVIG remain a controversy with studies stating for and against being equally vocal. In this article, we report a case of severe COVID-19 patient presenting with bilateral pneumonia, impending respiratory failure, acute kidney injury, and high risk for arteriovenous thromboembolism administered with IVIG therapy for 3 days. Patient saw improvement in his clinical condition several days following the final dose. Based on the outcome and pre-existing literatures, IVIG is recommended to be taken as an early consideration for those presenting with severe-critical COVID-19, particularly with suspected cytokine storm marked by high inflammatory value.


Keywords: IVIg, COVID-19, Immunoglobulin


Edition: Volume 11 Issue 4, April 2022,


Pages: 230 - 235

Intravenous Immunoglobulin Treatment on a Patient Presenting with Severe COVID-19 and Impending Respiratory Failure: A Case Report


How to Cite this Article?

Ary Priadnyana, Anak Agung Gde Upeksha, "Intravenous Immunoglobulin Treatment on a Patient Presenting with Severe COVID-19 and Impending Respiratory Failure: A Case Report", International Journal of Science and Research (IJSR), https://www.ijsr.net/get_abstract.php?paper_id=SR22401145642, Volume 11 Issue 4, April 2022, 230 - 235, #ijsrnet

How to Share this Article?

Enter Your Email Address






Top